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Objective To evaluate whether immunomodulation at start of enzyme replacement therapy induces immune tol-
erance to recombinant human acid alpha-glucosidase (rhGAA) in patients with classic infantile Pompe disease.
Study design Three patients (1 cross reactive immunologic material negative, 2 cross reactive immunologic ma-
terial positive) were treated with 4 weekly doses of rituximab, weekly methotrexate, and monthly intravenous im-
munoglobulin and enzyme replacement therapy at 40 mg/kg/week. Antibody titers were measured using enzyme-
linked immunosorbent assay. Neutralizing effects on rhGAA activity and cellular uptake were determined and combined
with pharmacokinetic analysis. Clinical efficacy was evaluated by (ventilator-free) survival, reduction in left ven-
tricular mass index, and improvement of motor function.
Results Immunomodulation induced B cell depletion that was accompanied by absence of antibody formation in
all 3 patients. Upon cessation of rituximab treatment, all 3 patients showed B cell recovery, which was accompa-
nied by formation of very high sustained antibody titers in 2 patients. Neutralizing effects on infused rhGAA were
low to mild/moderate. All patients were alive at study end, learned to walk, and showed (near) normalization of left
ventricular mass index.
Conclusions Immunomodulation as recommended in the literature prevented formation of rhGAA antibodies only
during B cell depletion but failed to induce immune tolerance in 2 out of 3 patients. (J Pediatr 2018;195:236-43).
P ompe disease (Glycogen Storage Disease type II, OMIM: #232300) is an autosomal recessive lysosomal storage disor-der caused by deficiency of the enzyme acid-a-glucosidase (GAA), and results in lysosomal glycogen accumulation withprominent pathology in cardiac and skeletal muscle cells.1 Pompe disease presents as a spectrum of clinical pheno-
types. The classic infantile form is the most severe, with residual alpha-glucosidase activity in cultured fibroblasts of less than
1%. About two-thirds of the patients with classic infantile Pompe disease produce inactive GAA protein, and they are, there-
fore, called cross-reactive immunologic material (CRIM) positive; one-third does
not produce any detectable GAA protein, and these patients are called CRIM
negative.Without treatment, patients with classic infantile Pompe disease die within
the first year of life because of cardiorespiratory failure.2-4
Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA,
alglucosidase alfa, Myozyme) has led to significant improvement of the pros-
pects of patients with classic infantile Pompe disease, but the clinical response to
ERT is heterogeneous: nearly one-half of patients do not survive ventilator-free
beyond the age of 3 years.5-9 One of the factors that may reduce the efficacy of
ERT is the formation of antibodies to rhGAA that neutralize its activity or prevent
its cellular uptake.10-13 Antibodies potentially pose a threat to survival because classic
infantile patients are strongly dependent on ERT.14-16 In general, a CRIM nega-
tive status is associated with high probability to form anti-rhGAA antibodies and
a poor clinical outcome.11,12 However, many CRIM positive classic infantile and
some childhood/adult onset patients with Pompe (which are by definition CRIM
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positive), also develop high anti-rhGAA antibody titers. The
likelihood to form high and sustained antibody titers is dif-
ficult to predict.11,12,17,18
In 2012, prevention of antibody formation was shown by
immunomodulation/immune tolerance induction at the start
of ERT.19,20 The protocol consisted of a 4-week treatment with
rituximab (RTX), and additional treatment with methotrex-
ate (MTX) and intravenous immunoglobulin (IVIG). The ra-
tionale was to prevent formation of B memory cells at the start
of ERT by eliminating B cells with RTX during the initial 4
weeks of ERT.MTXwas used as additional immunomodulatory
agent, and IVIG supplementation was applied to prevent op-
portunistic infections.
We implemented this primary immunomodulation
protocol19,20 in our patients, and monitored: formation of anti-
rhGAA antibodies, depletion and repopulation of B cells, effects
of antibodies on GAA enzyme activity and cellular uptake, and
clinical outcome. Furthermore, we determined the effects of
antibodies during infusion with ERT.
Methods
Study protocols were approved by the Institutional Review
Board, and written informed consent was obtained from the
parents. Standardized assessments were performed at base-
line, on a monthly basis during the first 3 months, and every
3 months thereafter as described by van den Hout et al.6
Immunomodulation consisted of intravenous RTX 375 mg/
m2/dose, weekly for 4 weeks followed by intravenous MTX
1mg/kg/dose based onMessinger et al andMendelsohn et al.19,20
The first dose of RTX was administered the day before the first
dose of alglucosidase alfa dosed at 40 mg/kg/week. MTX was
given directly after RTX 1 day before the infusion during the
first 4 weeks and from week 5 onward weekly MTX was given
directly after ERT infusion. IVIG at 400 mg/kg was given
monthly starting at week 4 until B cell levels and IgG levels
had reached normal values for age. Antibiotic prophylaxis was
given to prevent (respiratory) infections. Regular blood analy-
sis consisted of assessing number of neutrophils, number of
B and T cells, aspartate transaminase (AST), alanine trans-
aminase (ALT), creatine kinase, and gamma globulin (IgG, IgM,
IgA) levels. MTX was temporarily discontinued when neu-
trophil counts were below 0.50 × 10^9 g/L, AST/ALT levels
became more elevated than expected based on the disease
course, or when patients had a temperature >38.5°C
Patients treated for at least 24 months with ERT and
immunomodulation were included. Immunomodulation was
performed in patients, regardless of their CRIM status, who
were older than 2 months of age at the start of ERT, as these
might have the highest risk to develop high anti-rhGAA an-
tibody titers.12 Here we report on the first 3 patients from our
center who received immunomodulation. Classic infantile
Pompe disease was defined as symptoms of muscle weakness
within 6 months after birth, the presence of hypertrophic car-
diomyopathy, confirmed deficiency of endogenous
a-glucosidase in fibroblasts of <1% of the normal mean, and
mutation analysis.
Clinical outcome was evaluated by (ventilator-free) sur-
vival. Cardiac dimensions were measured by conventional
echocardiography according to the recommendations of the
American Society of Echocardiography; left ventricular mass
index (LVMI) was calculated by the Devereux formula and
indexed by body surface area. An LVMI of >+2SD of age-
related peers was considered abnormal.21,22 Motor function was
assessed by Alberta Infant Motor Scale (AIMS), Bayley Scales
of Infant Development II, and by recording motor
milestones.23,24 Infusion-associated reactions (IARs) were noted
when they occurred.
Anti-rhGAA titers were assessed at baseline, 4, 8, and 12
weeks after start of ERT and thereafter every 3 months. Stan-
dardized antibody analysis was performed by an enzyme-
linked immunosorbent assay (ELISA) as described.12,17,18
Antibody titers were measured in a 5-fold serial dilution to de-
termine the antibody titer range. When a positive titer was
found, a 2-fold serial dilution was used to obtain a more precise
titer. The highest titer measured was used. Samples were mea-
sured in duplicate per assay, and assays were performed at least
twice. The background of the ELISA method was deter-
mined to be 1:250 by omitting the coating of the plates with
rhGAA as described previously.17
Blood was drawn before start of infusion with alglucosidase
alfa, at several preset time points during the infusion, and after
completion. Plasma or serumwas prepared and stored at −80°C
until use. The effect of antibodies during infusion of ERT was
determined by capturing antibody-rhGAA complexes using
protein A or G sepharose, followed by analysis of the super-
natant on rhGAA enzyme activity by 4-MU assay as described18
and rhGAA protein content by mass spectrometry as
described.25 Results obtained using protein A or protein G
sepharose were similar.
Neutralizing effects of antibodies were measured as
described.12,17 In short, to fibroblasts from a patient com-
pletely deficient for endogenous GAA activity, 20 µL of the pa-
tient’s serumwas added along with 200 nmol rhGAA for a total
volume of 200 µL Ham’s-F10+ medium containing 3 mM
PIPES and antibiotics. Enzyme activity was measured in
medium and in cell lysate and compared with the activity in
a fetal calf serum sample (set at 100%).
For in vitro analysis, 10 nmol rhGAA in 10 µL Phosphate
buffered saline (PBS) was incubated with various dilutions of
patient’s sera in the presence of 40 µL protein A/sepharose for
1 hour at room temperature. The mixture was centrifuged for
2 minutes at 12 000 RPM in an Eppendorf centrifuge. Enzyme
activity in the supernatant was measured and compared with
the results obtained with sera from control individuals.
Results
Patient characteristics are given in Table I. Patient 1 was ho-
mozygous for c.525delT, which leads to undetectable GAAmes-
senger RNA or protein expression. This patient was, therefore,
CRIM negative.26 Patient 2 was homozygous for c.1551+1G>A.
Immunoblot analysis showed that thisGAA variant led to GAA
protein production, and the patient was, therefore, CRIM
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positive (Figure 1; available at www.jpeds.com). This is in agree-
ment with splicing analysis of this variant, which indicated that
it causes a perfect skip of exon 10 in which the reading frame
remains intact.27 Patient 3 contained the c.525delT and the
c.2481+102_2646+31del (delex18) GAA variants, the latter of
which expresses a truncated GAA protein, and, therefore, this
patient was also CRIM positive.28
Patients started ERT at a relatively late age (5.8, 4.3, and 3.1
months). At start of ERT, all 3 patients were able to move and
lift arms and legs from the surface, showed poor head balance,
and none were able to roll over. AIMS scores were clearly below
the fifth percentile in all 3 patients. Two patients required oxygen
by nasal prong, the other was monitored at night because of
superficial breathing. All required nasogastric tube feeding and
had a hypertrophic cardiomyopathy (Table I). The LVMI value
was the highest in patient 2, who showed additional dilated
cardiomyopathy (Table I). To exclude other possible causes of
cardiac disease in this patient, exome sequence analysis of a
panel of 49 genes known to be involved in hypertrophic car-
diomyopathy was performed (Table II; available at
www.jpeds.com). No other pathogenic variant was found.
The number of B cells decreased to undetectable levels after
start of RTX treatment, and normalized in all patients after
RTX was stopped. Time to B cell recovery was 6.7 months
(patient 1); 6.7 months (patient 2); and 7.7 months (patient
3) (Figure 2). T cells remained within normal values through-
out the study in all 3 patients (data not shown). During B cell
depletion, all patients received IVIG; this was continued after
B cell recovery until gamma globulin levels remained within
the normal range for age (>3.5 g/L). IVIGwas stopped in patient
1 at 18.7 months after start of immunomodulation and in
patient 2 at 12.6 months. At study end, patient 3 still needed
IVIG with 2- to 3-month intervals. These results indicate that
all 3 patients responded to the immunomodulatory treat-
ment with a rapid and transient B cell depletion.
The immunomodulation regimen was well tolerated. Pa-
tients 1 and 3 showed a mild skin reaction during the first dose
of RTX. In patient 2, the third RTX infusion was skipped
because of a concomitant bacterial infection at that time. In
patient 1, MTX treatment was temporarily suspended at 11
months after start of immunomodulation for 4 weeks because
of unanticipated increase of AST and ALT levels. MTX was re-
started at a lower dose of 0.5 mg/kg/week. In total, 9 of the
weekly MTX administrations were skipped over the course of
24 months (Figure 2). In patient 3, 1 dose of MTX was skipped
because of low neutrophil count 21 months after start. IARs
during alglucosidase alfa infusions occurred only in patient 1.
Fifteen mild IARs and 3 severe IARs were observed (as defined
in Table III; available at www.jpeds.com). The age at the first
IAR was 6.7 months (infusion 5; first asterisk in Figure 2, A).
Antihistamines were administered before the next infusions
and the infusion rate was adapted.Antihistamines were stopped
at age 8.5 months (infusion 14). Infusion rates were gradu-
ally adapted to higher rates, starting at the age of 14 months
(8.2 months of ERT). This process was still ongoing at the age
of 20.7 months (14.8 months of ERT) when he experienced
a new IAR (second asterisk in Figure 2). At that time, infu-
sion rates were slowed down again and antihistamines and cor-
ticosteroids were started. With this regimen, IARs remained
variably present until the end of the study period.
Antibody titers as measured with ELISA are shown in
Figure 2. In patient 1, anti-rhGAA antibodies were first de-
tected at 4.5 months of ERT (titer 1:1250) and continued to
increase to a maximum titer of 1:800 000 at 13 months of ERT.
In patient 2, anti-rhGAA antibodies were undetectable during
the first 9 months of ERT. At 12 months of ERT, the antibody
Table I. Patient characteristics
Characteristics Patient 1 Patient 2 Patient 3
At baseline
Sex Male Female Male
Age at diagnosis (mo) 5.7 4.0 2.9
Age at start of ERT (mo) 5.8 4.3 3.1
GAA variants c.525delT c.1551+1G>A c.525delT
c.525delT c.1551+1G>A c.2481+102_2646+31del
CRIM status* Negative Positive Positive
Enzyme activity in fibroblasts/leucocytes† 0.3/1.6 0.1/1.6 0.4/1.3
LVMI at baseline/z score‡ 265/26.1 753/87.8 160/12.8
AIMS at baseline (percentile score) 4 (p < 5) 3 (p < 5) 3 (p < 5)
At study end
Age (mo) 34 28.2 27.0
LVMI/z score 65/0.7 87/3.5 72/1.6
Maximum motor milestone (age achieved in mo) Walking (21.3) Walking (18.0) Walking (17.3)
Number of IARs (number of severe IARs) 15 (3) 0 0
Peak antibody titer (mo of ERT treatment) 800 000 (13) 6250 (14) 200 000 (14)
B cell recovery (time in mo)§ 6.7 6.7 7.7
B cell level (age at study end)§ 1.25*10E9 (30.2) 0.75*10E9 (25.4) 0.67*10E9 (22.4)
IgG level (age at study end)¶ 4.6 (30.2) 6.5 (25.4) 3.3 (22.4)
*CRIM status in patient 1 and 3 was based on known effects of GAA variants. In patient 2, CRIM status was assessed by immunoblot analysis of fibroblasts (Figure 1).
†Enzyme activity in nmol/h/mg (fibroblasts: 4-MU substrate; leucocytes: 4-MU substrate + acarbose). Normal range fibroblasts: 45-180 nmol/hr/mg. Normal range leucocytes: 6.7-27 nmol/hr/mg.
‡LVMI in g/m2.
§Time to B cell recovery in months after the last dose of RTX. B cell normal range: 0.2-2.1*10E9.
¶IgG normal range: 3.5-10.0 g/L.
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titer was 1:1250 and increased to an intermediate maximum
titer of 1:6250 at 14 and 21 months of ERT. In patient 3, anti-
rhGAA antibodies were detected at 2 months of ERT (1:6250),
and increased to a very high maximum titer of 1:200 000 at
14 months of ERT. The start of antibody formation coin-
cided with B cell recovery. Titers remained high in patients 1
and 3, and fluctuated between intermediate and background
levels in patient 2 during follow up (Figure 2). These results
indicated that the immunomodulation procedure induced a
temporarily suppression of antibody formation during B cell
ablation, while it failed to induce immune tolerance.
To test for neutralizing effects of antibodies, GAA-deficient
fibroblasts were incubated with alglucosidase alpha plus pa-
tients’ serum, followed by enzyme activity measurements in
medium and cell lysates (Figure 2). The latter was taken as
the sum of neutralizing effects on cellular uptake and inhibi-
tion of enzymatic activity. A reference patient that we re-
ported previously,18 served as a positive control for detection
of neutralizing antibodies; this patient showed an enzyme ac-
tivity of 29.7% in the cell lysate (data not shown). No neu-
tralizing effects of antibodies in the medium were found
(enzyme activities in all case were >92% of control; data not
shown). In patients 1, 2, and 3, enzyme activities in cell lysates
were 79.8%, 105%, and 94.8% as percentage of control at 20,
14, and 14 months of ERT, respectively (Figure 2; gray crosses,
right axis), indicating moderate (patient 1) to no (patients 2
and 3) neutralizing effects. However, at 27 months of ERT,
neutralizing effects of antibodies in patient 1 were more pro-
nounced and indicated 60% residual enzyme activity in cell
lysates.
Figure 2. Immunologic responses during immunomodulation. Each column represents a single patient. A, Anti-rhGAA anti-
body titers (black symbols, left y-axis) and neutralizing effects of anti-rhGAA antibodies (gray crosses on right y-axis). The in-
tracellular rhGAA activity is determined by incubation of fibroblasts with patient serum plus rhGAA (alglucosidase alfa) and is
expressed as percentage of control serum (fetal calf serum). Black asterisk indicates the first and subsequent IAR in patient 1.
Dashed gray lines represent background levels of the ELISA. B, B cells levels; dashed gray lines indicate normal values in
serum. C, Total IgG levels; dashed gray lines indicate normal values in serum. D, Immunomodulation schedule per patient, each
line represents treatment duration. In patient 1 and 3, the black asterisk indicates missed MTX injection(s); in patient 2 black
asterisk indicates missed RTX infusion.
April 2018 ORIGINAL ARTICLES
239High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start
of Enzyme Replacement Therapy
To determine the effect of anti-rhGAA antibodies on rhGAA
enzymatic activity during ERT, serum samples collected at
several time points during infusion were used for immuno-
precipitation with protein A-sepharose, followed by measure-
ment of rhGAA activity in the supernatant (Figure 3, A).
Sepharose only served as control. The analysis was per-
formed at 20, 14, and 14 months of ERT for patients 1, 2, and
3, respectively. The amount of precipitated alglucosidase alfa
activity in serum samples collected during infusion was close
to zero in all 3 patients (Figure 3, A), suggesting that protein
A-bound alglucosidase alfa was either enzymatically inactive
or not present. To distinguish between these possibilities, we
used mass spectrometry to detect alglucosidase alfa protein in-
dependent of enzyme activity, as reported by us recently.25
Figure 3, B shows that the percentages of antibody-bound
rhGAA protein were 37.7%, 2.7%, and 11.8% in patients 1,
2, and 3, respectively. We conclude that the anti-rhGAA an-
tibodies in these patients preferentially bound to infused rhGAA
protein that was enzymatically inactive.
To test the effect of anti-rhGAA antibodies on enzymatic
activity in a cell-free assay, we incubated a fixed amount of
rhGAA with increasing amounts of patient’s serum, fol-
lowed by immunoprecipitation with protein A and measure-
ment of enzyme activity in the supernatant. Serum from the
reference patient with known neutralizing effects of antibod-
ies efficiently precipitated alglucosidase alfa activity (Figure 5;
available at www.jpeds.com, gray line). In contrast, serum from
patients 2 and 3 failed to precipitate alglucosidase alfa activ-
ity in vitro (Figure 5, squares and triangles). Patient 1 showed
moderate capacity to precipitate alglucosidase alfa activity at
20 months of ERT (Figure 5, filled circles). However, when
tested 7months later (month 27), serum from patient 1 showed
enhanced capacity to precipitate alglucosidase alfa activity
(Figure 5, open circles), with an efficiency that was almost as
strong as that of the reference patient. We conclude from
these data that in patient 1, titers of antibodies with neutral-
izing effects increased from 20 to 27 months of ERT, and
patients 2 and 3 did not show detectable neutralizing
antibodies.
At study end, all 3 patients survived ventilator-free. LVMI
z score decreased significantly in all 3 patients and normal-
ized completely in patients 1 and 3. It was still slightly el-
evated in patient 2 at study end (LVMI 87 g/m2, z score 3.5;
SD 7.9, Figure 4, C),21 and cardiac dilatation had disap-
peared and the shortening fraction normalized to 40% (data
not shown). Motor function improved. All patients learned to
walk independently at ages of 21, 18, and 17 months (pa-
tients 1, 2, and 3, respectively), and AIMS and Bayley Scales
of Infant Development II scores increased accordingly (Figure 4,
A and B). Nasogastric feeding tube could be withdrawn at ages
of 15.8, 10, and 9months.Oxygen supply andmonitoring could
be stopped after 3, 13.5, and 6 months of ERT. At the age of
29 months (24 months of ERT), patient 1 temporarily lost the
ability to walk after a foot injury (Figure 4, B). At the age of
Figure 3. Pharmacokinetic profile of alglucosidase alfa activity and alglucosidase alfa protein during infusion with ERT. A,
Alglucosidase alfa activity measured in serum before and during infusion with rhGAA. Closed symbols represent the total rhGAA
enzyme activity. Open symbols represent serum that was first subjected to immunoprecipitation with protein A, which captures
rhGAA bound to anti-rhGAA antibodies. The remaining rhGAA enzyme activity in the supernatant was measured and used to
calculate the percentage of antibody-bound enzymatically active GAA. Results using protein G were similar. B, The experi-
ment described in the upper row was now analyzed by mass spectrometry rather than enzyme activity and reports values for
antibody-bound rhGAA protein irrespective of their enzymatic activity. Closed symbols represent the total rhGAA protein in sera;
open symbols the antibody-bound rhGAA protein in sera.
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34 months (28 months of ERT), he regained the ability to walk
(albeit with lesser stability than before).
Discussion
The results of our study and other published studies on primary
immunomodulation are summarized in Table IV (available at
www.jpeds.com).Messinger et al described the effects of tran-
sient immunomodulation in 2 ERT naïve patients. One patient
remained antibody-free for up to 2 years following cessation
of transient RTX treatment, and the other patient developed
a titer of 1:1500 at 7 months, which dropped to 1:400 after 18-
24 months.19 This group, using a slightly different transient
immunomodulation protocol, also reported another patient
who had low antibody titer of 1:3200 at 12 months.31 On the
other hand, a report by Elder et al found high antibody titers
in the first patient 5 months after receiving transient
immunomodulation.29 This patient died 8 months later,
and the authors decided to continue RTX treatment in the fol-
lowing 4 patients to suppress antibody formation. That
same year, Banugaria et al published a decision flow
chart in which patients with increasing antibody titers after
transient immunomodulation received a second round of
immunomodulation, which was applied to 2 out of 7 patients.30
Broomfield et al reported on 9 patients receiving transient
immunomodulation and only 1 developed an antibody titer.15
In the present study, 2 out of 3 patients with our transient
immunomodulation protocol developed very high antibody
titers upon B cell recovery. Although other reports suggested
that transient treatment with RTX plus MTXmay induce long-
term immune tolerance,19,20,30,31 our results indicate that this
protocol may induce a transient suppression of antibody for-
mation rather than immune tolerance in certain patients. It
should be noted that although all of these studies used RTX
to eliminate B cells, variations existed with respect to
additional treatments. For example, the duration and dosage
of MTX treatment varied, and in some cases MTX was re-
placed by mycophenolate or sirolimus (Table IV). Also, the age
at which ERT and immunomodulation was started varied
between patients and ranged between 0.1 and 8 months of age
(median 3.1 months). It is unknown to what extent these varia-
tions affect the immunomodulatory outcome. Clinical
outcome of previously published patients that received
immunomodulation was heterogeneous (Table IV). Of the 24
patients, 5 patients died (21%), and only 6 learned to walk
(25%). In contrast, in the present study all 3 patients sur-
vived at study end and learned to walk.A likely important factor
that contributed to the positive clinical outcome in the present
study is the high dosage of rhGAA (40 mg/kg/week), which
has previously been shown to have a beneficial effect com-
pared with the standard dosage of 20 mg/kg every 2 weeks.13
The patients in the previously published studies received
either 20 mg/kg every 2 weeks or 20 mg/kg/week, Broom-
field et al reported 2 patients in whom the dose was in-
creased to 40 mg/kg/week.15 Another factor to be considered
is CRIM status. A negative CRIM status has been associated
with a poor prognosis, reduced response to ERT, and ten-
dency to form high antibody titers.10-12 The majority of pub-
lished patients in Table IV were CRIM negative, in line with
the poor clinical outcome of these patients. However, patient
1 of the present study was also CRIM negative, yet survived
and learned to walk, even though he started ERT the latest at
the age of 5.8 months. Because antibodies in this patient only
showedmild tomoderate neutralizing effects (discussed below),
we hypothesize that the high dosage of rhGAA may have been
responsible for his relatively good clinical outcome at study
end.
The very high antibody titers detected using ELISA showed
mild to moderate (patient 1) to no (patients 2 and 3) neu-
tralizing effects in vitro in cell-based assays (Figure 2), a cell-
free assay (Figure 5), and on serum samples collected during
Figure 4. Effects of ERT and immunomodulation on clinical outcome. A, Motor function measured by AIMS; B, Motor function
measured by Bayley Scales of Infant Development II. Raw scores were translated to age equivalent scores to compare pa-
tients. Patient 1 lost the ability to walk at the age of 29 months (first black arrow) and regained this ability at the age of 34
months (second black arrow). C, LVMI z score. Normal values depend on body surface area as described by Poutanen et al.21
For a body surface area up to 0.75 normal values are 59.2 g/m2 with an SD of 7.9 g/m2.
BSID-II, Bayley Scales of Infant Development II.
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infusion with rhGAA (Figure 3, A). These assays have been
shown to be capable of detecting neutralizing effects of
antibodies, as highlighted previously.17,18 Whether the
immunomodulation protocol has influenced the nature or IgG
subclasses of anti-GAA antibodies remains to be investigated
in future analysis by comparing sera of patients who under-
went immunomodulation or not. It is of concern that in patient
1, neutralizing effects increased from mild (~20%) in the first
year to moderate (~40%) around study end (27 months of
ERT). A limitation of the present study is the relatively short
follow-up after cessation of RTX treatment and the low number
of patients. Future work should be directed toward longer
follow-up of formation of neutralizing antibodies and the ef-
ficacy of ERT in a larger cohort. To translate neutralizing effects
measured in vitro to the situation in patients, one needs to take
into account the dosage of ERT. At a higher dosage em-
ployed here, it is expected that neutralizing effects will be less
severe compared with a regular dosage, as more antibody-
free rhGAA will be available.
The inclusion of mass spectrometry as a read out for anti-
bodies revealed a surprise: a considerable percentage of rhGAA
protein was captured by antibodies during infusion in patient
1 (37%), but only a small fraction (2 %) of enzymatically active
GAA was captured (comparing Figure 3, A and B). This sug-
gests that infused rhGAAmay undergo denaturation upon pro-
longed exposure to conditions present in the circulation. In
agreement, we found that the half-life of rhGAA enzymatic ac-
tivity in blood in vitro is only 100 minutes, while full length
rhGAA protein remains detectable over prolonged periods.32
In tissue culture medium and in the cellular fraction, we did
not find evidence that antibodies from patients promoted deg-
radation of rhGAA, although a larger study is required to
confirm this. The ELISA assay cannot distinguish between an-
tibodies directed toward native or denatured proteins, sug-
gesting that ELISA titers per se are insufficient to predict
potential deleterious effects of antibodies, and that addi-
tional analysis using neutralizing assays are required to more
accurately link antibody formation to clinical outcome.
Although immunomodulation of ERT naïve patients with
Pompe disease using a combination of RTX, MTX, and IVIG
has been reported to be associated with prevention of anti-
body formation,19,20 we showed that this treatment induces
immune suppression during B cell depletion rather than tol-
erance in 2 out of 3 patients in our study. It will be important
to optimize protocols that can provide long-term prevention
of antibody formation without compromising general immu-
nity in patients with Pompe disease treated with ERT. ■
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50 Years Ago in The Journal of Pediatrics
A Search for the Reservoir of Cytomegalovirus in Salivary Gland Tissue
ven Bensel RW, St Geme JW Jr. J Pediatr 1968;72:479-82
I n this publication, ven Bensel and St Geme, Jr, described an unsolved mystery, 60 years after the description of cy-tomegalic inclusion disease and 10 years after the first isolation of cytomegalovirus (CMV): what was the manner
of CMV acquisition beyond neonatal disease? They observed that the 80% seropositivity rate of persons older than 35
years of age described in the literature at the time was similar to that for herpes simplex. Recognizing that acquisition
and probable latency occurred without symptoms, they postulated that the salivary glands could be a primary site of
latency, with transmission and occasional disease the result of reactivation and salivary shedding.
Extracting salivary gland tissue immediately at necropsies, they sought microscopic evidence of cytomegalic inclu-
sion disease and attempted isolation of CMV in tissue culture. A total of 100 unselected patients older than 10 years
of age whose autopsies were performed at the University of Minnesota Medical Center over 1 year’s time were sub-
jects (31 acute accidental or surgical deaths, 47 deaths from cancer, and 22 from chronic systemic illnesses). Their results
fit into a single sentence: They found no evidence of CMV cytopathic effect or positive culture in even 1 of 100 specimens.
Case closed? We know that CMV is shed in saliva, genital secretions, breast milk, and urine (the first 3 serving as
major sources/vehicles of transmission) and is latent in mononuclear cells and several organs. Congenital, primary,
and reactivation infection can lead to either, neither, or both silent infection or devastating disease, depending on the
host. Saliva is a highly sensitive specimen source to screen newborns for congenital CMV infection via polymerase chain
reaction testing. So why did the authors not find any reactivating salivary gland virus, with more than one half of sub-
jects dying of cancer or another disease and thus presumably immunocompromised? This writer could speculate but
really has no idea. Their premise was correct.
Reliving this time in clinical virology 50 years ago was special for this writer. Isolation of CMV in tissue culture,
then, took a spectacular mean of about 30 days. The other more poignant memory was of JosephW. St Geme, Jr, whom
I had the privilege to know a bit, throughWaldo E. Nelson and his team at St Christopher’s Hospital for Children. Joe
St Geme—a wonderful man and scientist and believer in young people and the future of pediatrics—lives on through
his family, through the leadership award bearing his name that is given annually at the Pediatric Academic Societies
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Figure 1. Immunoblot analysis of patient 2. Cell homogenates
were prepared as described in Van Gelder et al 2015.12 Equal
amounts of protein were loaded per lane. The 2 lanes are control
fibroblasts from a healthy individual and fibroblasts from patient
2. Patient 2 shows a specific band at ~105.8 kD, which is con-
sistent with the size of the 110 kD precursor GAA protein minus
4.2 kD, caused by an in-frame skip of exon 10.27
Serum (µL)
Figure 5. Antibody titers determined by immunoprecipitation under cell-free conditions. A fixed amount of rhGAA was incubated
with various amounts of patient serum in vitro in the absence of cells, and anti-rhGAA antibodies were immunoprecipitated with
protein A/G. The enzyme activity of rhGAA in the supernatant was used to determine the percentage of antibody-bound enzy-
matically active rhGAA (relative to control serum, using the reference patient with known neutralizing antibodies as described
by de Vries et al in 2010).18 Anti-rhGAA titers at time of analysis were 1:800 000 (patient 1, both time points); 1:200 000 (patient
2); and 1:6250 (patient 3).
Table II. Exome sequence analysis of 49 genes involved
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Table III. IARs in patient 1
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Table IV. Overview of the literature of immunomodulation in patients with classic infantile Pompe naïve to ERT
Authors Year Pt Allele 1 Allele 2
Age
start






















2012 3 c.2560C>T c.2560C>T 16 wk 24 mo Yes Yes Yes 1A 5 wk No 30 m Yes 1:1600 (2 m) ND
4 c.1548G>A c.525delT 15 wk 24 mo Yes Yes Yes 1A 5 wk No 17 m Yes 0 (9 m) ND
Elder et al29 2013 A c.2560C>T c.2560C>T 8 mo 11 mo No No No 2A 5 wk No 10 m Yes 1:500 000 (5 m) ND
B c.1396delG c.1705dup 8 mo 36 mo Yes No† No 2B RTX ongoing No <12 wk No NA ND
C c.925G>A c.925G>A 2.75 mo 30 mo Yes Yes No 2B RTX ongoing No <12 w No NA ND
D c.1548G>A not found 6 mo 24 mo Yes Yes No 2B RTX ongoing No <12 wk No NA ND
E c.1933G>A c.2501_2502del 3 mo 22 mo Yes Yes No 2C RTX ongoing No <12 w No NA ND
Banugaria
et al30
2013 1 c.2608C>T c.2608C>T 3.0 mo 101 wk Yes Yes No 1E 5 wk No 96 wk Yes 0 (81 w) ND
2 c.546+2T>C c.546+2T>C 4.1 mo 92 wk Yes NIV No 1E 5 wk No 87 w Yes 0 (67 w) ND
3 c.236_246del c.236_246del 2.4 mo 89 wk Yes Yes Yes 1E 5 wk No 84 w Yes 0 (69 w) ND
4 c.525delT c.2560C>T 0.1 mo 70 wk Yes No No 1E 5 wk No 65 w ND 0 (NA) ND
5 c.2560C>T c.2560C>T 0.5 mo 59 wk Yes NIV No 1E 5 wk Yes 24 w No 1:6400 (before) ND
6 c.525_526delTG c.525_526delTG 1 mo 51 wk Yes NIV No 1E 5 wk Yes 8 w No 1:6400 (before) ND
7 c.2560C>T c.2560C>T 1 mo 48 wk No No No 1E 5 wk No 43 w Yes 0 (8 w) ND
Stenger
et al31
2015 1 c.2105G>T c.2512C>T 1.2 mo 17 mo Yes Yes Yes 1B 5 wk No 39 w Yes 1:3200 (39 w) ND
Broomfield
et al15
2016 6 c.525delT c.2608C>T 4.7 mo 4.2 mo No No No 1C 5 wk No ~6 m Yes 0 (>4-9 m) ND
7 c.2608C>T c.2608C>T 6.6 mo 5.4 mo Yes Yes No 1C 5 wk No ~3 w Yes 0 (0.6 y) ND
8 c.2237G>A c.2237G>A 2.4 mo 9.6 mo No No No 1C 5 wk No ~9 m Yes 0 (>4-9 m) ND
12 c.2078dup c.2078dup 6.7 mo 8.9 mo Yes Yes No 1C 5 wk No ~16 m Yes 0 (0.9 y) ND
14 c.2560C>T c.2560C>T 18 d 17.5 mo No No No 1C 5 wk No ~17 m Yes 0 (>4-9 m) ND
16 c.2237G>A c.2237G>A 36 wk* 33 mo Yes Yes Yes 1C 5 wk No ~31 m Yes 0 (>4-9 m) ND
17 c.2560C>T c.2560C>T 5.2 mo 28.4 mo Yes Yes Yes 1C 5 wk No ~28 m Yes 0 (1.8y) ND
19 c.525delT c.2481+102_2646+31del 3.9 mo 32.9 mo Yes NIV Yes‡ 1C 5 wk No ~32 m Yes 1:12 800 (1.3 y) ND
22 c.877G>A c.877G>A 2.2 mo 49.4 mo Yes NIV No 1C 5 wk No ~49 m Yes 0 (2.5 y) ND
This study 2017 1 c.525delT c.525delT 5.8 mo ~24 mo Yes Yes Yes 1D MTX ongoing No 23 m Yes 1:800 000 (6.3 m) mild/moderate
2 c.1551+1G>A c.1551+1G>A 4.2 mo ~24 mo Yes Yes Yes 1D MTX ongoing No 23 m Yes 1:6250 (7.3 m) No
3 c.525delT c.2481+102_2646+31del 3.1 mo ~24 mo Yes Yes Yes 1D MTX ongoing No 23 m Yes 1:200 000 (6.3 m) No
IM, immunomodulation; NA, not applicable; ND, not determined; Neg, negative; NIV, noninvasive ventilation; Pos, positive.
Immunomodulation (IM) treatment used per study: 1A RTX 375 mg/m2/dose for 4 doses; MTX 0.4 mg/kg/dose subcutaneous for 9-17 doses; IVIG 500 mg/kg administered once in patient 1. 1B RTX 375 mg/m2/dose for 4 doses; MTX 15 mg/m2/dose oral for 9
doses; IVIG 400-500 mg/kg twice. 1C RTX 375 mg/m2/dose for 1-4 doses; MTX 0.4 mg/kg/dose subcutaneous for 10-18 doses. 1D RTX 375 mg/m2/dose for 4 doses; MTX 1 mg/kg/wk intravenous for the duration of follow up; IVIG 400 mg/kg monthly. 1E RTX
375 mg/m2/dose for 4 doses; MTX 0.4 mg/kg/dose subcutaneous for 9 doses; IVIG 400-500 mg/kg 5-6 times. 2A RTX 750 mg/m2/dose for 2 doses; Mycophenolate 300 mg/m2/day oral; IVIG 500-1000 mg/kg monthly. 2B RTX 375 mg/m2/dose for 3 doses + repeat
RTX every 12 weeks; Sirolimus 0.6-1 mg/m2/day oral; IVIG 500-1000 mg/kg monthly. 2C RTX 750 mg/m2/dose for 2 doses+ repeat RTX every 12 weeks; Sirolimus 0.6-1 mg/m2/day oral; IVIG 500-1000 mg/kg monthly.
*Patient 16 in Broomfield et al was born at 34 weeks of gestational age and ERT was initiated at 36 weeks of gestational age.
†Patient B became ventilator dependent after follow-up.
‡Patient 19 lost ability to walk 4 months after gaining it, within follow-up period.
§Ref 15: B cell recovery 4-9 months after last RTX; Personal communication, A. Broomfield.
¶Time after B cell recovery in ref 15 was 4-9 months after last RTX, time given here in age when tested.
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